Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,437 | 101 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Journey Medical Corporation | $677.06 | 6 | $0 (2024) |
| Galderma Laboratories, L.P. | $588.65 | 6 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $412.84 | 15 | $0 (2024) |
| PFIZER INC. | $260.93 | 18 | $0 (2021) |
| Celgene Corporation | $249.65 | 7 | $0 (2019) |
| Incyte Corporation | $170.22 | 3 | $0 (2023) |
| Amgen Inc. | $154.62 | 6 | $0 (2024) |
| GENZYME CORPORATION | $153.70 | 7 | $0 (2024) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $136.10 | 2 | $0 (2021) |
| Almirall LLC | $101.08 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $327.13 | 10 | Journey Medical Corporation ($123.43) |
| 2023 | $501.55 | 15 | E.R. Squibb & Sons, L.L.C. ($336.01) |
| 2022 | $376.99 | 9 | Journey Medical Corporation ($115.84) |
| 2021 | $642.11 | 10 | Galderma Laboratories, L.P. ($258.49) |
| 2020 | $115.91 | 6 | GENZYME CORPORATION ($45.28) |
| 2019 | $529.53 | 8 | Galderma Laboratories, L.P. ($166.15) |
| 2018 | $638.91 | 32 | Journey Medical Corporation ($127.22) |
| 2017 | $305.29 | 11 | Galderma Laboratories, L.P. ($79.76) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $30.12 | General |
| Category: Inflammation | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $22.33 | General |
| Category: Immunology | ||||||
| 08/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Dermatology | ||||||
| 06/14/2024 | Journey Medical Corporation | — | Food and Beverage | In-kind items and services | $123.43 | General |
| 05/22/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.72 | General |
| Category: Immunology | ||||||
| 05/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: Immunology | ||||||
| 05/08/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $21.00 | General |
| Category: Immunology | ||||||
| 02/28/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $13.78 | General |
| Category: Immunology | ||||||
| 01/29/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.77 | General |
| Category: Inflammation | ||||||
| 11/28/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.82 | General |
| Category: Dermatology | ||||||
| 11/01/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.21 | General |
| Category: Immunology | ||||||
| 10/16/2023 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: DERMATOLOGY | ||||||
| 09/28/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.45 | General |
| Category: Immunology | ||||||
| 08/30/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $3.38 | General |
| Category: Immunology | ||||||
| 08/16/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.13 | General |
| Category: Immunology | ||||||
| 08/03/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.40 | General |
| Category: Immunology | ||||||
| 07/31/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $133.33 | General |
| 05/22/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $139.40 | General |
| Category: Immunology | ||||||
| 04/24/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.36 | General |
| Category: Immunology | ||||||
| 04/19/2023 | Journey Medical Corporation | — | Food and Beverage | In-kind items and services | $107.40 | General |
| 04/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $4.26 | General |
| 03/08/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.52 | General |
| Category: Immunology | ||||||
| 03/02/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.57 | General |
| Category: Immunology | ||||||
| 03/01/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,270 | 3,663 | $267,481 | $108,597 |
| 2022 | 10 | 1,318 | 3,784 | $265,756 | $107,072 |
| 2021 | 10 | 1,447 | 4,386 | $293,446 | $125,146 |
| 2020 | 8 | 1,215 | 3,517 | $236,725 | $89,673 |
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 236 | 362 | $59,730 | $29,738 | 49.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 267 | 425 | $48,590 | $24,815 | 51.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 296 | 523 | $57,007 | $21,646 | 38.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 117 | 146 | $22,630 | $10,395 | 45.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 260 | 2,062 | $49,488 | $9,564 | 19.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 43 | 71 | $21,442 | $8,316 | 38.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 21 | 40 | $5,920 | $2,970 | 50.2% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 15 | 19 | $1,444 | $588.41 | 40.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 15 | 15 | $1,230 | $564.45 | 45.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 363 | $58,860 | $28,670 | 48.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 266 | 416 | $45,110 | $24,142 | 53.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 309 | 524 | $57,116 | $21,691 | 38.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 263 | 2,180 | $52,320 | $10,145 | 19.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 111 | 136 | $21,080 | $9,305 | 44.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 46 | 72 | $21,744 | $8,274 | 38.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 17 | 34 | $5,032 | $2,746 | 54.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 18 | 21 | $1,722 | $820.44 | 47.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 13 | 22 | $1,672 | $780.21 | 46.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 16 | $1,100 | $496.59 | 45.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 252 | 363 | $54,450 | $30,893 | 56.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 301 | 501 | $50,100 | $29,953 | 59.8% |
| 17000 | Destruction of skin growth | Office | 2021 | 326 | 587 | $63,983 | $23,784 | 37.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 296 | 2,574 | $61,776 | $11,662 | 18.9% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 126 | 155 | $24,025 | $11,644 | 48.5% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 58 | 86 | $25,972 | $10,293 | 39.6% |
About Dr. Connie Sutter, MD
Dr. Connie Sutter, MD is a Dermatology healthcare provider based in Independence, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164487534.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Connie Sutter, MD has received a total of $3,437 in payments from pharmaceutical and medical device companies, with $327.13 received in 2024. These payments were reported across 101 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($3,437).
As a Medicare-enrolled provider, Sutter has provided services to 5,250 Medicare beneficiaries, totaling 15,350 services with total Medicare billing of $430,488. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Independence, OH
- Active Since 04/19/2006
- Last Updated 11/09/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1164487534
Products in Payments
- Otezla (Drug) $376.12
- Sotyktu (Drug) $275.25
- EUCRISA (Drug) $260.93
- OPZELURA (Drug) $170.22
- ORACEA (Drug) $166.15
- DUPIXENT (Biological) $165.72
- EPIDUO FORTE (Drug) $164.01
- Exelderm (Drug) $161.16
- Ceracade (Drug) $127.22
- JUBLIA (Drug) $124.44
- VTAMA (Drug) $98.74
- AKLIEF (Drug) $97.78
- Finacea (Drug) $86.70
- Veltin (Drug) $47.54
- Seysara (Drug) $35.63
- Erivedge (Biological) $28.74
- Enbrel (Biological) $28.15
- Alcortin A (Drug) $26.12
- OLUMIANT (Drug) $24.21
- DUPIXENT DUPILUMAB INJECTION (Biological) $23.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Independence
Mary Sivik, Md, MD
Dermatology — Payments: $6,621
Dr. Farhaad Riyaz, Md, MD
Dermatology — Payments: $3,633
Anand Rajpara, M.d, M.D
Dermatology — Payments: $3,092
Carol Burg, Md, MD
Dermatology — Payments: $2,476
Marlene Willen, Md, MD
Dermatology — Payments: $1,474
Peter Muelleman
Dermatology — Payments: $436.97